Evaluation of efficacy of QR 678 and QR678 neo hair growth factor formulation for the treatment of female pattern alopecia in patients with PCOS-A prospective study.
PCOS
QR678
QR678 Neo
androgenic alopecia
female pattern hair loss
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
27
07
2020
revised:
07
08
2020
accepted:
10
08
2020
entrez:
18
1
2021
pubmed:
19
1
2021
medline:
15
5
2021
Statut:
ppublish
Résumé
Hair is an essential identity of women. Femininity, sexuality, attractiveness, and personality are symbolically linked to a woman's hair. Female pattern hair loss is found in 20%-30% of patients with polycystic ovary syndrome (PCOS). The aim of the present study was to evaluate the efficacy of QR678 A total of 20 females diagnosed with PCOS in the age 25-50 years, with complaints of female pattern alopecia with Ludwig, grades I, and II were selected for the study. At each visit, 1.5 ml solution of QR678 Marked improvement was seen in the global photographic assessment score (mean = 8) which was maintained for over 1 year. In videomicroscopic assessment, after four sessions the patients had 8.07 fewer vellus hair, 6.07 more terminal hair, and average hair shaft diameter was 0.82 μm wider. After eight sessions, they had 11.66 fewer vellus hair, 13.77 more terminal hair, and hair shaft diameter was 2.86 μm wider than at baseline. Intra-dermal injections of QR 678
Sections du résumé
BACKGROUND
BACKGROUND
Hair is an essential identity of women. Femininity, sexuality, attractiveness, and personality are symbolically linked to a woman's hair. Female pattern hair loss is found in 20%-30% of patients with polycystic ovary syndrome (PCOS).
AIM
OBJECTIVE
The aim of the present study was to evaluate the efficacy of QR678
METHOD
METHODS
A total of 20 females diagnosed with PCOS in the age 25-50 years, with complaints of female pattern alopecia with Ludwig, grades I, and II were selected for the study. At each visit, 1.5 ml solution of QR678
RESULT
RESULTS
Marked improvement was seen in the global photographic assessment score (mean = 8) which was maintained for over 1 year. In videomicroscopic assessment, after four sessions the patients had 8.07 fewer vellus hair, 6.07 more terminal hair, and average hair shaft diameter was 0.82 μm wider. After eight sessions, they had 11.66 fewer vellus hair, 13.77 more terminal hair, and hair shaft diameter was 2.86 μm wider than at baseline.
CONCLUSION
CONCLUSIONS
Intra-dermal injections of QR 678
Substances chimiques
Intercellular Signaling Peptides and Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2637-2646Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Cruz C, Costa C, Gomes A, Matamá T, Cavaco-Paulo A. Human Hair and the Impact of Cosmetic Procedures: A Review on Cleansing and Shape-Modulating Cosmetics. Cosmetics. 2016;3:26.
Scalzo K, McKittrick M. Case problem: dietary recommendations to combat obesity, insulin resistance, and other concerns related to polycystic ovary syndrome. J Am Diet Assoc. 2000;100:955-957.
Cela E, Robertson C, Rush K, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol. 2003;149:439-442.
Franks S. Polycystic Ovary Syndrome. N Engl J Med. 1995;333(13):853-861.
Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7:219-231.
Boyle JA, Cunningham J, OˈDea K, Dunbar T, Norman RJ. Prevalence of polycystic ovary syndrome in a sample of Indigenous women in Darwin, Australia. Med J Aust. 2012;196:62-66.
Ma YM, Li R, Qiao J, et al. Characteristics of abnormal menstrual cycle and polycystic ovary syndrome in community and hospital populations. Chin Med J (Engl). 2010;123:2185-2189.
Gill H, Tiwari P, Dabadghao P. Prevalence of polycystic ovary syndrome in young women from North India: A community-based study. Indian J Endocrinol Metab. 2012;16:S389-S392.
Joshi B, Mukherjee S, Patil A, Purandare A, Chauhan S, Vaidya R. A cross-sectional study of polycystic ovarian syndrome among adolescent and young girls in Mumbai, India. Indian J Endocrinol Metab. 2014;18:317-324.
Nidhi R, Padmalatha V, Nagarathna R, Amritanshu R. Prevalence of polycystic ovarian syndrome in Indian adolescents. J PediatrAdolesc Gynecol. 2011;24:223-227.
Nair MKC, Pappachan P, Balakrishnan S, Leena ML, George B, Russell PS. Menstrual irregularity and poly cystic ovarian syndrome among adolescent girls- a 2 year follow-up study. Indian J Pediatr. 2012;9:S69-73.
Christodoulopoulou V, Trakakis E, Pergialiotis V, et al. Clinical and Biochemical Characteristics in PCOS Women With Menstrual Abnormalities. J Fam Reprod Health. 2016;10:4.
Fabbrocini G, Cantelli M, Masarà A, Annunziata MC, Marasca C, Cacciapuoti S. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. Int J Womens Dermatol. 2018;4:203-211.
Dinh QQ, Sinclair R. Female pattern hair loss: Current treatment concepts. Clin Interv Aging. 2007;2:189-199.
Carmina E, Azziz R, Bergfeld W, et al. Female pattern hair loss and androgen excess: a report from the multidisciplinary androgen excess and PCOS committee. J Clin Endocrinol Metab. 2019;104(7):2875-2891.
Gainder S, Sharma B. Update on management of polycystic ovarian syndrome for dermatologists. Indian Dermatol Online J. 2019;10:97-105.
Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study. J Cosmet Laser Ther. 2018;20:369-379.
ArsieContin L. Male androgenetic alopecia treated with microneedling alone or associated with injectable minoxidil by microinfusion of drugs into the skin. Surg Cosmet Dermatol. 2016;8:158-161.
Kapoor R, Shome D, Vadera S, Kumar V, Ram MS. QR678 & QR678 Neo Hair Growth Formulations: A Cellular Toxicity & Animal Efficacy Study. Plast Reconstr Surg Global Open. 2020;8(2843):1-13. https://journals.lww.com/prsgo/Abstract/9000/QR678___QR678_Neo_Hair_Growth_Formulations__A.97136.aspx
National Institutes of Health. Evidence-based methodology workshop on polycystic ovary syndrome, 2012. Executive summary.
Fauser BCJM, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): The Amsterdam ESHRE/ASRM- Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28-38.e25.
Hunt N, McHale S. The psychological impact of alopecia. BMJ. 2005;331:951-953.
Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev. 1999;20:535-582.
Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol. 2004;60:1-17.
Harwood K, Vuguin P, DiMartino-Nardi J. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Horm Res. 2007;68:209-217.
Huang A, Brennan K, Azziz R. Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. FertilSteril. 2010;93:1938-1941.
Lobo RA. Infertility, Contraception, and Reproductive Endocrinology, 3rd edn. Cambridge, UK: (Blackwell Scientific Publications; 1991;447-487.
Olsen EA. Female pattern hair loss. J Am Acad Dermatol. 2002;45:S70-80.
Etcoff N. Survival of the Prettiest: The Science of Beauty. New York, NY: Doubleday; 1999.
Goldberg LJ, Lenzy Y. Nutrition and hair. Clin Dermatol. 2010;28:412-419.
Finner AM. Nutrition and hair: Deficiencies and supplements. Dermatol Clin. 2013;31:167-172.
Guo EL, Katta R. Diet and hair loss: Effects of nutrient deficiency and supplement use. Dermatol Pract Concept. 2017;7:1-10.
Blumeyer A, Tosti A, Messenger A, et al. Evidence-based guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. 2011;9:S1-57.
Herskovitz I, Tosti A. Female pattern hair loss. Int J Endocrinol Metab. 2013;11(4):e9860.
Varothai S, Bergfeld WF. Androgenetic alopecia: An evidence-based treatment update. Am J Clin Dermatol. 2014;15:217-230.
Friedman ES, Friedman PM, Cohen DE. Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. J Am Acad Dermatol. 2002;46:309-312.
Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2010;65:6.
Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Design Dev Ther. 2019;13:2777-2786.
Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136-141.e5.
American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776-789.
Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57:104-109.
Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2009;75:47-51.
Iorizzo M, Vincenzi C, Voudouris S, Piraccini BM, Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol. 2006;142:298-302.
Olsen EA, Hordinsky M, Whiting D, et al. Dutasteride Alopecia Research Team. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo- controlled study of dutasteride versus finsteride. J Am Acad Dermatol. 2006;55:1014-1023.
Camacho F, Tosti A. Medical treatment of female alopecia. Monogr Dermatol. 2005;18(92):59.
Hamblin MR, Demidova TN, eds. Mechanisms of low level light therapy. Biomedical optics. 2006.
Avram MR, Leonard RT Jr, Epstein ES, Williams JL, Bauman AJ. The current role of laser/light sources in the treatment of male and female pattern hair loss. J Cosmet Laser Ther. 2007;9:27-28.
Leavitt M, Charles G, Heyman E, Michaels D. HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: A randomized, double-blind, sham device-controlled multicenter trial. Clin Drug Investig. 2009;29:283-292.
Yazdabadi A, Green J, Sinclair R. Successful treatment of female-pattern hair loss with spironolactone in a 9-year-old girl. Australas J Dermatol. 2009;50:113-114.
Adamopoulos DA, Karamertzanis M, Nicopoulou S, Gregoriou A. Beneficial effect of spironolactone on androgenic alopecia. Clin Endocrinol (Oxf). 1997;47:759-760.
Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol. 1985;112:124-125.
Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005;152:466-473.
Levy LL, Emer JJ. Female pattern alopecia: current perspectives. Int J Women's Health. 2013;5:541-556.
Simard J, Luthy I, Guay J, Bélanger A, Labrie F. Characteristics of interaction of the antiandrogenflutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol. 1986;44:261-270.
Paradisi R, Porcu E, Fabbri R, Seracchioli R, Battaglia C, Venturoli S. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother. 2011;45(469-75):52.
Bruni V, Peruzzi E, Dei M, et al. Hepatotoxicity with low- and ultralow-dose flutamide: a surveillance study on 203 hyperandrogenic young females. Fertil Steril. 2012;98:1047-1052.
Dhurat R, Sukesh MS, Avhad G, Dandale A, Pal A, Pund P. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. Int J Trichol. 2013;5:6-11.
Dhurat R, Mathapati S. Response to microneedling treatment in men with androgenetic alopecia who failed to respond to conventional therapy. Indian J Dermatol. 2015;60:260-263.
Kiichiro Y, Brown LF, Michael D. Control of hair growth & follicle size by VEGF-mediated angiogenesis. J Clin Invest. 2001;107:409-417.
Kozlowska U, Blume-Peytavi U, Kodelja V, et al. Expression of vascular endothelial growth factor (VEGF) in various compartments of the human hair follicle. Arch Dermatol Res. 1998;290:661-668.
Danilenko DM, Ring BD, Yanagihara D, et al. Keratinocyte growth factor is an important endogenous mediator of hair follicle growth, development, & differentiation. Normalization of the nu/nu follicular differentiation defect & amelioration of chemotherapy-induced alopecia. Am J Pathol. 1995;147:145-154.
Kapoor R, Shome D, Vadera S, Ram S. QR678 & QR678 Neo Vs PRP- A randomized, comparative, prospective study. J Cosmet Dermatol. 2020;00:1-9.
Unger WP, Unger RH. Hair transplanting: An important but often forgotten treatment for female pattern hair loss. J Am Acad Dermatol. 2001;49:5.